An effective universal cure or broadly curative therapy for most major cancers is approved by the FDA before 2

Question

Six frontier AI models put this at 3% by 16 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

3% — the median of 6 frontier models, resolving by 2036-10-16.

Answer

Gemini (Google): 2% — Cancers are biologically too heterogeneous for a single shared therapy to reliably induce complete remission across most major types. No single mechanism or antigen exists across carcinomas, sarcomas, and hematologic malignancies to allow one universal therapy. A drug entering Phase 1 by 2027 would face a sub-10% historical trial success rate and takes 8-12 years to secure pan-cancer FDA approval. A breakthrough in universal immune targets like invariant TCRs showing durable remission across >5 solid tumors would alter this view.

Answer

Claude (Anthropic): 2% — Cancer is hundreds of distinct diseases; a single universal curative therapy contradicts current biology and drug development pathways. No single mechanism (CAR-T, mRNA, checkpoint inhibitors) works broadly across solid and liquid tumors with reliable complete remission. FDA approvals remain indication-specific; a 'universal cure across major cancer types' would require dozens of pivotal trials, not one approval. Current trajectory is toward personalized combination therapies, not convergence on one curative agent, making this scenario structurally unlikely by 2036.

Answer

GPT (OpenAI): 7% — The bottleneck is proving durable, broad remission across biologically distinct cancers in FDA-grade trials. FDA would need to approve one therapy with reliable complete remissions in most major tumor types by October 2036. Past platform breakthroughs—checkpoint inhibitors, CAR-T and targeted drugs—have transformed subsets, not most solid cancers. Odds rise sharply if a phase III pan-tumor therapy shows durable remissions across common lung, breast, colorectal and pancreatic cancers.

Answer

Grok (xAI): 3% — One FDA-approved agent must induce reliable complete remissions across most major solid and hematologic cancers. Phase 3 programs plus FDA review for a first-in-class pan-cancer therapy typically consume 8–12 years even after a striking Phase 1 signal. No precedent exists: CAR-T, checkpoint inhibitors and mRNA vaccines remain lineage- or mutation-restricted with incomplete responses. A 2027–28 multi-tumor registrational trial showing >70 % durable CR in lung, breast, colon and pancreas would be the only development that could move the needle.

Answer

DeepSeek (DeepSeek): 4% — A single therapy that reliably cures most major cancers is a category error, not a regulatory milestone. Cancer is hundreds of genetically distinct diseases; a pan-cancer cure would require a mechanism common to all, which decades of research have not found. FDA approves drugs for specific indications, not 'most cancers' — even pembrolizumab's tissue-agnostic approval covers only ~1-2% of tumors. The 10-year window is too short for the fundamental biology problem to be solved, let alone cleared through Phase III trials and FDA review.

Answer

Qwen (Alibaba): 2% — Cancer is hundreds of distinct diseases; no single mechanism has ever shown cross-type curative efficacy. No therapy in any pipeline stage has demonstrated reliable complete remission across solid tumor types; CAR-T and checkpoint inhibitors remain subtype-specific. Even a hypothetical breakthrough entering Phase I today faces 8-12 years of oncology trial timelines, leaving almost no slack before Oct 2036. The biological heterogeneity of major cancers (different drivers, microenvironments, immune evasion) makes a single curative mechanism implausible without a…

An effective universal cure or broadly curative therapy for most major cancers is approved by the FDA before 2036.

What each one said

An effective universal cure or broadly curative therapy for most major cancers is approved by the FDA before 2036.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.